Monashee Investment Management’s BridgeBio Pharma BBIO Stock Holding History

Monashee Investment Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.99M	Sell	67,139 -32,861	-33%	-$2.38M	2.71%	11
2025 Q4	$7.65M	Sell	100,000 -100,000	-50%	-$6.56M	4.31%	9
2025 Q3	$10.4M	Sell	200,000 -55,000	-22%	-$2.68M	5.18%	1
2025 Q2	$11M	Buy	255,000 +80,000	+46%	+$2.91M	3.99%	6
2025 Q1	$6.05M	Buy	+175,000	New	+$5.9M	0.72%	20
2024 Q2	–	Sell	-60,000	Closed	-$1.86M	–	83
2024 Q1	$1.86M	Buy	+60,000	New	+$2.04M	0.22%	73
2019 Q3	–	Sell	-50,000	Closed	-$1.35M	–	123
2019 Q2	$1.35M	Buy	+50,000	New	+$1.36M	0.35%	76

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Monashee Investment Management's BBIO Position: Q1 2026 in Review

Monashee Investment Management reduced its BridgeBio Pharma (BBIO) stake by 33% in Q1 2026, selling an estimated $2.38M and leaving 67,139 shares worth $4.99M. The position accounts for 2.71% of the portfolio, ranked #11.

Monashee Investment Management first reported a position in BBIO in Q2 2019 and has held it in 7 quarters since. The position peaked at $11M in Q2 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Monashee Investment Management held 67,139 shares of BridgeBio Pharma worth $4.99M as of Q1 2026.
Monashee Investment Management sold 32,861 BridgeBio Pharma shares in Q1 2026, an estimated $2.38M.
BridgeBio Pharma made up 2.71% of Monashee Investment Management's portfolio in Q1 2026, its #11 holding.
Monashee Investment Management first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 7 quarters since.
Monashee Investment Management's BridgeBio Pharma position peaked at $11M in Q2 2025.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Monashee Investment Management's 13F filing for Q1 2026, filed 13 May 2026.